Cystotech develops AI-driven applications for cystoscopy that enhance diagnostic accuracy and enable less invasive treatment approaches for bladder cancer. The technology addresses the high recurrence rate of bladder cancer by improving the correlation between visual tumor grade estimation and actual tumor characteristics, thereby optimizing surgical resection depth.
Funding
Funding not disclosed
Founders
Product
Problem
Visual estimation of tumor grade during cystoscopy is poorly correlated with actual tumor grade, leading to high recurrence rates and delayed adjuvant treatment for bladder cancer patients. Current methods often result in incorrect resection depth during primary tumor removal.
Solution
Cystotech develops AI-driven software as a medical device (SaMD) to improve the diagnostic performance of cystoscopies and enable less invasive bladder cancer treatments. CystoAID, their flagship product, supports clinicians during both flexible and rigid cystoscopies by providing real-time AI-based decision support. The software enhances the correlation between visual tumor grade estimation and actual tumor characteristics, optimizing surgical resection depth. By improving diagnostic accuracy, Cystotech aims to reduce recurrence rates, improve patient outcomes, and transform the clinical pathway for bladder cancer treatment.
Target Audience
The primary target audience includes urologists, hospitals, and healthcare providers who perform cystoscopies for bladder cancer diagnosis and treatment.
Features
- AI-powered image analysis for real-time tumor grade estimation during cystoscopy
- Support for both flexible and rigid cystoscopy procedures
- Integration with existing cystoscopy equipment via software interface
- Algorithms trained on a large dataset of bladder cancer cases to improve accuracy
- MDR certification for the European market